Munich - Delayed Quote EUR

Immunocore Holdings plc (6YG.MU)

31.40

+0.80

+(2.61%)

At close: January 31 at 5:26:51 PM GMT+1

Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 113.1% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 18 days ago

IMCR
Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

Reaching more mUM patients globally with KIMMTRAK (tebentafusp) in 2025 through additional launches and increased community penetration Enrolling three Phase 3 trials across multiple melanoma indications – potential data readouts beginning with TEBE-AM in 2026 Enrolling Phase 1/2 trial with brenetafusp combinations in ovarian and lung cancer; ongoing dose escalation with IMC-R117C (PIWIL1) and IMC-P115C (PRAME-A02-HLE) Presenting initial HIV Phase 1 MAD data in the first quarter 2025 Progressing

GlobeNewswire 21 days ago

IMCR
Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 6 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in in a p

GlobeNewswire 25 days ago

IMCR
Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune dis

GlobeNewswire 29 days ago

IMCR
Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME IMC-P115C (PRAME-HLE-A02) targets the same peptide and has the same CD3 effector and TCR specificity as brenetafusp, and is designed with extended half-life The Phase 1 trial will assess the safety and clinical activity of IMC-P115C in HLA-A*02:01-positive patients with advanced solid tumors that express PRAME (OXFORDSHIRE, England & C

GlobeNewswire last month

IMCR
Immunocore doses first subject in gastrointestinal cancer therapy trial

The therapy is the fifth ImmTAC molecule from the company to enter clinical trials.

Clinical Trials Arena last month

IMCR
Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First immunotherapy program to target PIWIL1, a cancer-testis antigen overexpressed in a range of cancers, including colorectal cancer (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 17 December 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage

GlobeNewswire last month

IMCR
Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

Morgan Stanley downgraded Amicus Therapeutics Inc (NASDAQ:FOLD). Over the last year, the company has executed well commercially, met its goals financially by achieving nonGAAP profitability for 2024, and settled its Galafold patent litigation with Teva Pharmaceutical Industries Ltd. The analyst notes that Amicus is well-positioned, but expectations have increased with the company’s progress, which are now largely priced into shares. The analyst downgraded the stock to Equal-weight from Overweigh

Benzinga last month

IMRX

FOLD

IMCR
All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy

Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks last month

IMCR
Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial

The European Organisation for Research and Treatment of Cancer and Immunocore (IMCR) Holdings announced the randomization of the first patient in the Phase 3 Adjuvant Trial in Ocular Melanoma, investigating the safety and efficacy of tebentafusp as adjuvant treatment for uveal melanoma. The primary objective of the open-label, international, multicenter trial – led by EORTC – will be to assess whether tebentafusp can prevent or delay relapse in patients with primary ocular melanoma at high risk

TipRanks last month

IMCR
EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

ATOM is the only active Phase 3 trial for adjuvant treatment of uveal melanoma The trial will assess whether adjuvant treatment with tebentafusp can decrease the risk of relapse, compared to observation (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 11 December 2024) The European Organisation for Research and Treatment of Cancer (EORTC), an independent clinical cancer research organization focusing on improving the standards of cancer treatments for patients to prolong surviva

GlobeNewswire last month

IMCR
Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 03 December 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious

GlobeNewswire last month

IMCR
Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 112.8% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 2 months ago

IMCR
Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode

We recently compiled a list of the 10 Best Small-Cap Stocks Ready To Explode. In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against the other small-cap stocks. Prospects For Extended Outperformance Of Small-Cap Stocks On October 7, Chuck Royce, founder and Senior Advisor, and Francis Gannon, Co-Chief […]

Insider Monkey 2 months ago

IMCR

^RUT
Is Immunocore Holdings plc (IMCR) the Best Immunotherapy Stock to Buy Now?

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion […]

Insider Monkey 2 months ago

IMCR
Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 112.6% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 2 months ago

IMCR
Immunocore to present at upcoming investor conferences

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 8 November 2024) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conferences in November. Guggenheim Securities Healthcare

GlobeNewswire 2 months ago

IMCR
Immunocore reports third quarter financial results and provides a business update

Immunocore reports third quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $80.2 million in 3Q 2024, 28% growth over 3Q 2023 Phase 3 trials in cutaneous melanoma ongoing (PRISM-MEL-301 and TEBE-AM); and Phase 3 trial in adjuvant uveal melanoma (ATOM) to start randomizing in 4Q 2024 Presented Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients; ongoing signal detection in metastatic NSCLC will shift initial data release; focus

GlobeNewswire 2 months ago

IMCR
Immunocore (IMCR) Upgraded to Buy: Here's Why

Immunocore (IMCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 2 months ago

IMCR
Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ...

Immunocore Holdings PLC (IMCR) reports a 34% increase in net sales, driven by robust US market performance and strategic global initiatives, despite challenges in Europe.

GuruFocus.com 3 months ago

IMCR

Performance Overview

Return	6YG.MU	MSCI WORLD
YTD	+15.44%	+3.16%
1-Year	-48.10%	+19.69%
3-Year	+67.91%	+25.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immunocore Holdings plc (6YG.MU)

Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

Immunocore to present at the 43rd Annual J.P. Morgan Healthcare Conference

Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

Immunocore announces first patient dosed in the Phase 1 trial of IMC-P115C, a half-life extended (HLE) ImmTAC candidate in patients with tumors that express PRAME

Immunocore doses first subject in gastrointestinal cancer therapy trial

Immunocore announces treatment of first patient in the Phase 1/2 trial of IMC-R117C targeting PIWIL1 in advanced gastrointestinal cancers

Why Are Amicus, Immunocore, & Immuneering Stocks Trading Lower On Friday?

All You Need to Know About Immunocore (IMCR) Rating Upgrade to Strong Buy

Immunocore, EORTC announce enrollment of first patient in Phase 3 ATOM trial

EORTC and Immunocore announce enrolment of first patient onto the only active Phase 3 adjuvant trial in uveal melanoma

Immunocore announces reimbursement agreement in England for KIMMTRAK▼ for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma

Does Immunocore (IMCR) Have the Potential to Rally 112.82% as Wall Street Analysts Expect?

Immunocore Holdings plc (IMCR): This Small-Cap Stock Is Ready To Explode

Is Immunocore Holdings plc (IMCR) the Best Immunotherapy Stock to Buy Now?

Wall Street Analysts Predict an 112.56% Upside in Immunocore (IMCR): Here's What You Should Know

Immunocore to present at upcoming investor conferences

Immunocore reports third quarter financial results and provides a business update

Immunocore (IMCR) Upgraded to Buy: Here's Why

Immunocore Holdings PLC (IMCR) Q2 2024 Earnings Call Highlights: Strong US Growth and Strategic ...

Performance Overview